Oncoclínicas do Brasil Serviços Médicos (ONCO3) Stock Overview
Provides oncology, hematology, radiotherapy, and genomics healthcare services in Latin America. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
ONCO3 Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Oncoclínicas do Brasil Serviços Médicos S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | R$1.18 |
| 52 Week High | R$6.00 |
| 52 Week Low | R$0.99 |
| Beta | 0.88 |
| 1 Month Change | 13.46% |
| 3 Month Change | -2.48% |
| 1 Year Change | -74.24% |
| 3 Year Change | -88.40% |
| 5 Year Change | n/a |
| Change since IPO | -93.83% |
Recent News & Updates
Narrative Update • Jun 04
ONCO3: Higher Discount Rate And Lower P/E Will Likely Cap Upside
Analysts have adjusted their price target for Oncoclínicas do Brasil Serviços Médicos lower to reflect updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E. This results in an implied change in valuation that investors may want to compare against the current R$ share price.
Narrative Update • May 13
ONCO3: Upcoming Shareholder Meetings Will Shape Bullish Repricing Potential
Analysts have updated their price target for Oncoclínicas do Brasil Serviços Médicos to R$3.50, based on unchanged fair value assumptions but revised views on discount rate, revenue growth and profit margin that also result in a slightly higher implied future P/E of 54.22x. What's in the News Oncoclínicas do Brasil Serviços Médicos has scheduled a Special/Extraordinary Shareholders Meeting for April 30, 2026, giving investors a key date to watch for governance or capital structure decisions (Key Developments).Narrative Update • Apr 20
ONCO3: Upcoming Shareholder Meetings Will Drive Bullish Repricing Potential
Analysts have cut their price target on Oncoclínicas do Brasil Serviços Médicos to R$3.50 from R$8.67, reflecting updated assumptions for lower revenue growth, slimmer profit margins, a higher future P/E multiple and a slightly adjusted discount rate. What's in the News Oncoclínicas do Brasil Serviços Médicos S.A. has a Special and Extraordinary Shareholders Meeting scheduled for April 30, 2026.Recent updates
Narrative Update • Jun 04
ONCO3: Higher Discount Rate And Lower P/E Will Likely Cap Upside
Analysts have adjusted their price target for Oncoclínicas do Brasil Serviços Médicos lower to reflect updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E. This results in an implied change in valuation that investors may want to compare against the current R$ share price.Narrative Update • May 13
ONCO3: Upcoming Shareholder Meetings Will Shape Bullish Repricing Potential
Analysts have updated their price target for Oncoclínicas do Brasil Serviços Médicos to R$3.50, based on unchanged fair value assumptions but revised views on discount rate, revenue growth and profit margin that also result in a slightly higher implied future P/E of 54.22x. What's in the News Oncoclínicas do Brasil Serviços Médicos has scheduled a Special/Extraordinary Shareholders Meeting for April 30, 2026, giving investors a key date to watch for governance or capital structure decisions (Key Developments).Narrative Update • Apr 20
ONCO3: Upcoming Shareholder Meetings Will Drive Bullish Repricing Potential
Analysts have cut their price target on Oncoclínicas do Brasil Serviços Médicos to R$3.50 from R$8.67, reflecting updated assumptions for lower revenue growth, slimmer profit margins, a higher future P/E multiple and a slightly adjusted discount rate. What's in the News Oncoclínicas do Brasil Serviços Médicos S.A. has a Special and Extraordinary Shareholders Meeting scheduled for April 30, 2026.Narrative Update • Apr 01
ONCO3: Higher Required Returns And Lower Margins Will Likely Cap Upside
Analysts have revised their price target on Oncoclínicas do Brasil Serviços Médicos to R$1.60. The update reflects higher assumed discount rates, lower revenue growth and profit margin estimates, and a higher future P/E multiple in their models.
Narrative Update • Mar 17
ONCO3: January 2026 Shareholder Meeting Will Support Constructive Upside Outlook
Analysts have slightly reduced their R$ price target on Oncoclínicas do Brasil Serviços Médicos, citing a higher assumed discount rate and a modestly richer future P/E multiple, while keeping fair value, revenue growth and profit margin assumptions effectively unchanged. What's in the News Oncoclínicas do Brasil Serviços Médicos has scheduled a special and extraordinary shareholders meeting for January 7, 2026, in São Paulo, Brazil, at rua Augusta 1.562, 12th floor, Consolação (Key Developments).Narrative Update • Mar 03
ONCO3: Lower Risk Assumptions And 2026 Meeting Will Shape Balanced Outlook
Analysts have slightly raised their price target for Oncoclínicas do Brasil Serviços Médicos to R$2.66 from R$2.61. This change reflects updated views on discount rates, revenue growth assumptions, profit margins and future P/E levels.Narrative Update • Feb 17
ONCO3: Lower Margin Outlook Will Likely Limit Future Share Returns
Analysts have raised their price target for Oncoclínicas do Brasil Serviços Médicos, citing updated assumptions that include a fair value shift from R$1.50 to R$1.60, a lower discount rate, slightly adjusted revenue growth and profit margin expectations, and a modestly higher future P/E multiple. What's in the News Oncoclínicas do Brasil Serviços Médicos S.A. has scheduled a Special and Extraordinary Shareholders Meeting for January 7, 2026.Narrative Update • Feb 03
ONCO3: Higher Discount Rate And Shareholder Meeting Will Shape Balanced Outlook
Analysts have reduced their price target for Oncoclínicas do Brasil Serviços Médicos by about R$0.40. This reflects slightly higher discount rate assumptions and a lower future P/E multiple, partly offset by modest adjustments to revenue growth and profit margin expectations.Narrative Update • Jan 19
ONCO3: Higher Discount Rate And Lower P/E Will Restrain Future Returns
Analysts have trimmed their price target on Oncoclínicas do Brasil Serviços Médicos, citing a slightly higher discount rate and modestly lower revenue growth assumptions, partly offset by improved profit margin expectations and a lower assumed future P/E multiple. What's in the News Oncoclínicas do Brasil Serviços Médicos scheduled a Special and Extraordinary Shareholders Meeting for January 7, 2026, in São Paulo, Brazil, at rua augusta 1.562, 12 andar, Consolação (Key Developments).Narrative Update • Jan 05
ONCO3: Higher Margins And Shareholder Meeting Will Shape Balanced Outlook
Analysts have adjusted their price target for Oncoclínicas do Brasil Serviços Médicos lower, citing updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E that together point to a more conservative valuation profile. What's in the News Oncoclínicas do Brasil Serviços Médicos S.A. has scheduled a Special and Extraordinary Shareholders Meeting for January 7, 2026, in São Paulo, Brazil, at rua Augusta 1.562, 12 andar, Consolação, city and state of São Paulo (Key Developments).Narrative Update • Dec 19
ONCO3: Lower Margins And Reduced Earnings Multiple Will Pressure Future Returns
Analysts have modestly reduced their price target on Oncoclínicas do Brasil Serviços Médicos by approximately 25 percent, reflecting a slightly lower fair value and profit margin outlook that is only partially offset by improved revenue growth expectations and a modestly reduced discount rate. What's in the News A special and extraordinary shareholders meeting is scheduled for January 7, 2026, to be held at Rua Augusta 1.562, 12th floor, Consolação, São Paulo, Brazil (company event filing) Valuation Changes The Fair Value estimate has fallen significantly, moving from 2.0x to 1.5x.Analysis Article • Dec 18
Revenues Not Telling The Story For Oncoclínicas do Brasil Serviços Médicos S.A. (BVMF:ONCO3) After Shares Rise 38%
Oncoclínicas do Brasil Serviços Médicos S.A. ( BVMF:ONCO3 ) shareholders are no doubt pleased to see that the share...Narrative Update • Dec 04
ONCO3 Will Likely Benefit From Higher Margins Despite Increased Risk Profile
Analysts have modestly lowered their price target on Oncoclínicas do Brasil Serviços Médicos to reflect a reduced fair value estimate of R$3.16 from R$3.59, even as they factor in slightly faster revenue growth, improved profit margins, and a lower future P/E multiple under a higher perceived discount rate. What's in the News Oncoclínicas do Brasil Serviços Médicos has scheduled a Special and Extraordinary Shareholders Meeting for October 8, 2025, in São Paulo, Brazil, to address key corporate matters.Analysis Article • Dec 01
Is Oncoclínicas do Brasil Serviços Médicos (BVMF:ONCO3) Using Debt In A Risky Way?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysis Article • Oct 08
There's Reason For Concern Over Oncoclínicas do Brasil Serviços Médicos S.A.'s (BVMF:ONCO3) Massive 29% Price Jump
Oncoclínicas do Brasil Serviços Médicos S.A. ( BVMF:ONCO3 ) shareholders are no doubt pleased to see that the share...Narrative Update • Sep 21
Debt Reduction And Revenue Diversification Will Secure Future Stability
Despite a notable improvement in net profit margin and a sharply lower future P/E ratio indicating stronger profitability and valuation, the consensus analyst price target for Oncoclínicas do Brasil Serviços Médicos has been revised downward from R$4.49 to R$3.59. What's in the News Special/Extraordinary Shareholders Meetings scheduled for Sep 09, 2025, and Oct 08, 2025, at the company's São Paulo location.Narrative Update • Sep 06
Debt Reduction And Revenue Diversification Will Secure Future Stability
With both the discount rate and future P/E ratio remaining effectively unchanged, analysts have kept their price target for Oncoclínicas do Brasil Serviços Médicos steady at R$4.49. What's in the News Oncoclínicas do Brasil Serviços Médicos S.A. was removed from the Brazil IBRX Index.Analysis Article • Aug 22
Some Confidence Is Lacking In Oncoclínicas do Brasil Serviços Médicos S.A. (BVMF:ONCO3) As Shares Slide 33%
Oncoclínicas do Brasil Serviços Médicos S.A. ( BVMF:ONCO3 ) shareholders that were waiting for something to happen have...Analysis Article • Aug 16
These Analysts Think Oncoclínicas do Brasil Serviços Médicos S.A.'s (BVMF:ONCO3) Sales Are Under Threat
BOVESPA:ONCO3 1 Year Share Price vs Fair Value Explore Oncoclínicas do Brasil Serviços Médicos's Fair Values from the...Analysis Article • Jul 09
Is Oncoclínicas do Brasil Serviços Médicos (BVMF:ONCO3) Using Debt In A Risky Way?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
New Narrative • Apr 20
Debt Reduction And Revenue Diversification Will Secure Future Stability
Strategic partnerships and revenue diversification efforts aim to stabilize and enhance growth, reducing reliance on major clients and expanding market reach.Analysis Article • Feb 22
Earnings Tell The Story For Oncoclínicas do Brasil Serviços Médicos S.A. (BVMF:ONCO3) As Its Stock Soars 124%
Oncoclínicas do Brasil Serviços Médicos S.A. ( BVMF:ONCO3 ) shares have had a really impressive month, gaining 124...Analysis Article • Feb 19
Is Now An Opportune Moment To Examine Oncoclínicas do Brasil Serviços Médicos S.A. (BVMF:ONCO3)?
Oncoclínicas do Brasil Serviços Médicos S.A. ( BVMF:ONCO3 ), might not be a large cap stock, but it received a lot of...Analysis Article • Jan 08
Why We're Not Concerned Yet About Oncoclínicas do Brasil Serviços Médicos S.A.'s (BVMF:ONCO3) 30% Share Price Plunge
Unfortunately for some shareholders, the Oncoclínicas do Brasil Serviços Médicos S.A. ( BVMF:ONCO3 ) share price has...Analysis Article • Dec 30
Oncoclínicas do Brasil Serviços Médicos (BVMF:ONCO3) Has No Shortage Of Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysis Article • Nov 23
Oncoclínicas do Brasil Serviços Médicos S.A. (BVMF:ONCO3) Stocks Pounded By 29% But Not Lagging Market On Growth Or Pricing
Unfortunately for some shareholders, the Oncoclínicas do Brasil Serviços Médicos S.A. ( BVMF:ONCO3 ) share price has...Analysis Article • Nov 20
Oncoclínicas do Brasil Serviços Médicos' (BVMF:ONCO3) Problems Go Beyond Weak Profit
The market wasn't impressed with the soft earnings from Oncoclínicas do Brasil Serviços Médicos S.A. ( BVMF:ONCO3...Analysis Article • Nov 17
Oncoclínicas do Brasil Serviços Médicos S.A. Reported A Surprise Loss, And Analysts Have Updated Their Forecasts
There's been a notable change in appetite for Oncoclínicas do Brasil Serviços Médicos S.A. ( BVMF:ONCO3 ) shares in the...Analysis Article • Sep 27
With A 25% Price Drop For Oncoclínicas do Brasil Serviços Médicos S.A. (BVMF:ONCO3) You'll Still Get What You Pay For
Oncoclínicas do Brasil Serviços Médicos S.A. ( BVMF:ONCO3 ) shareholders that were waiting for something to happen have...Analysis Article • Aug 15
Here's What Analysts Are Forecasting For Oncoclínicas do Brasil Serviços Médicos S.A. (BVMF:ONCO3) After Its Second-Quarter Results
Last week, you might have seen that Oncoclínicas do Brasil Serviços Médicos S.A. ( BVMF:ONCO3 ) released its...Analysis Article • Aug 13
Oncoclínicas do Brasil Serviços Médicos (BVMF:ONCO3) Takes On Some Risk With Its Use Of Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analysis Article • Jul 16
Earnings Tell The Story For Oncoclínicas do Brasil Serviços Médicos S.A. (BVMF:ONCO3) As Its Stock Soars 27%
Oncoclínicas do Brasil Serviços Médicos S.A. ( BVMF:ONCO3 ) shareholders would be excited to see that the share price...Analysis Article • Jul 03
Is Now An Opportune Moment To Examine Oncoclínicas do Brasil Serviços Médicos S.A. (BVMF:ONCO3)?
While Oncoclínicas do Brasil Serviços Médicos S.A. ( BVMF:ONCO3 ) might not have the largest market cap around , it saw...Analysis Article • Jun 01
Investors Appear Satisfied With Oncoclínicas do Brasil Serviços Médicos S.A.'s (BVMF:ONCO3) Prospects As Shares Rocket 25%
Oncoclínicas do Brasil Serviços Médicos S.A. ( BVMF:ONCO3 ) shareholders are no doubt pleased to see that the share...Analysis Article • Apr 17
Oncoclínicas do Brasil Serviços Médicos S.A.'s (BVMF:ONCO3) Share Price Is Still Matching Investor Opinion Despite 27% Slump
Unfortunately for some shareholders, the Oncoclínicas do Brasil Serviços Médicos S.A. ( BVMF:ONCO3 ) share price has...Analysis Article • Apr 03
Oncoclínicas do Brasil Serviços Médicos' (BVMF:ONCO3) Earnings Are Weaker Than They Seem
Despite announcing strong earnings, Oncoclínicas do Brasil Serviços Médicos S.A.'s ( BVMF:ONCO3 ) stock was sluggish...Analysis Article • Mar 11
Oncoclínicas do Brasil Serviços Médicos (BVMF:ONCO3) Has A Somewhat Strained Balance Sheet
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analysis Article • Feb 17
What Does Oncoclínicas do Brasil Serviços Médicos S.A.'s (BVMF:ONCO3) Share Price Indicate?
While Oncoclínicas do Brasil Serviços Médicos S.A. ( BVMF:ONCO3 ) might not have the largest market cap around , it...Shareholder Returns
| ONCO3 | BR Healthcare | BR Market | |
|---|---|---|---|
| 7D | -10.6% | 2.5% | 0.5% |
| 1Y | -74.2% | -9.7% | 9.9% |
Return vs Industry: ONCO3 underperformed the BR Healthcare industry which returned -9.7% over the past year.
Return vs Market: ONCO3 underperformed the BR Market which returned 9.9% over the past year.
Price Volatility
| ONCO3 volatility | |
|---|---|
| ONCO3 Average Weekly Movement | 27.5% |
| Healthcare Industry Average Movement | 7.9% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in BR Market | 7.9% |
| 10% least volatile stocks in BR Market | 1.9% |
Stable Share Price: ONCO3's share price has been volatile over the past 3 months compared to the BR market.
Volatility Over Time: ONCO3's weekly volatility has increased from 18% to 27% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | n/a | Carlos Gil Ferreira | grupooncoclinicas.com |
Oncoclínicas do Brasil Serviços Médicos S.A., together with its subsidiaries, provides oncology, hematology, radiotherapy, and genomics healthcare services in Latin America. The company offers treatment services, including radiotherapy, hormone therapy, immunotherapy, port-a-cath, palliative care, target therapy, breast cancer hormone therapy, bone marrow transplant, non-oncological infusions, oral chemotherapy, and prostate cancer hormone therapy; and surgery procedures, such as breast, head and neck, lung, prostate cancer, stomach, bladder cancer, oncological, kidney cancer, gynecological, and testicular cancer. It also provides diagnostics services comprising pathological analysis, genetic testing, molecular journey, personalized medicine and individualized treatment, myelogram-bone marrow biopsy, and ONCO test-PDO.
Oncoclínicas do Brasil Serviços Médicos S.A. Fundamentals Summary
| ONCO3 fundamental statistics | |
|---|---|
| Market cap | R$1.19b |
| Earnings (TTM) | -R$3.84b |
| Revenue (TTM) | R$5.41b |
0.2x
P/S Ratio-0.3x
P/E RatioIs ONCO3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ONCO3 income statement (TTM) | |
|---|---|
| Revenue | R$5.41b |
| Cost of Revenue | R$3.83b |
| Gross Profit | R$1.57b |
| Other Expenses | R$5.42b |
| Earnings | -R$3.84b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Aug 06, 2026
| Earnings per share (EPS) | -3.44 |
| Gross Margin | 29.10% |
| Net Profit Margin | -71.05% |
| Debt/Equity Ratio | 536.5% |
How did ONCO3 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/17 23:38 |
| End of Day Share Price | 2026/06/17 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Oncoclínicas do Brasil Serviços Médicos S.A. is covered by 13 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Flavio Yoshida | BofA Global Research |
| Marcio Osako | Bradesco S.A. Corretora de Títulos e Valores Mobiliários |
| Yan Cesquim | BTG Pactual |